Damora Therapeutics, Inc.
Waltham, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Galecto is a clinical-stage biotechnology company developing novel small-molecule therapeutics that target the core biological drivers of fibrosis, inflammation, and cancer. Founded by leading scientists and biotech executives with more than a decade of research into galectin biology and LOXL2 modulation, the company has built deep expertise in pathways central to complex and often devastating dis
Key facts
- Headquarters
- Waltham, Massachusetts, United States
- Employees
- 18
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (DMRA)
- Website
- galecto.com
- Company page
Recent activity at Damora Therapeutics, Inc.
- : SEC 8-K (1.01):
- : SEC 8-K (5.02): On April 28, 2026, Damora Therapeutics, Inc. announced the departure of Lori Firmani as Chief Financial Officer, effective May 1, 2026. Ms. Firmani, who had served since August 2024, will receive separation benefits, including a lump sum payment for base salary continuation and pro-rated target bonus, a health savings account contribution of $6,000, and the acceleration of her equity awards. The Board appointed Brian Burkavage, the former Senior Vice President of Finance, as the new Chief Financial Officer and Principal Accounting Officer, effective the same day. Burkavage brings extensive experience from previous roles in finance at other companies and is a licensed CPA, ensuring continuity in the company’s financial leadership amidst this transition.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On March 9, 2026, Damora Therapeutics, Inc. issued a press release regarding its Name Change Amendment and Symbol Change, officially notifying stakeholders of the updates. The filing includes information that ensures compliance with Regulation FD, clarifying the non-materiality of the announcement in context with the Securities Exchange Act. The press release is attached as Exhibit 99.1, highlighting the corporate changes aimed at rebranding and possibly enhancing market visibility. This disclosure reflects a strategic decision to update the company's identity and symbol, potentially impacting shareholder perception and future market performance.
- : SEC 8-K (1.01): On February 10, 2026, Galecto, Inc. entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC for the offer and sale of 14,473,685 shares of the Company’s common stock at a public offering price of $19.00 per share. The Underwriters were granted a 30-day option to purchase an additional 2,171,052 shares, which they exercised fully on February 11, 2026. The net proceeds from this Offering are approximately $295.9 million, enabling the Company to fund operations into Phase 3 development of DMR-001. The Offering is expected to close on February 12, 2026, and includes indemnification clauses for the Underwriters against certain liabilities.
- : SEC 8-K (5.02): On February 6, 2026, Galecto, Inc. announced the departure of Chief Executive Officer and President Hans T. Schambye, effective February 10, 2026. Dr. Schambye will receive separation benefits, including base salary and a pro-rated bonus paid in a lump sum, as well as the acceleration of his outstanding equity awards. Additionally, on the same day, the Board appointed Sherwin Sattarzadeh, the current Chief Operating Officer, as the interim principal executive officer, effective at the same time. Mr. Sattarzadeh’s previous employment terms will continue under the existing offer letter, and his appointment was not influenced by any arrangement or understanding with third parties. This transition reflects the company’s strategic management changes that could impact its operational direction going forward.
- : SEC 8-K (7.01): Galecto, Inc. is conducting meetings with securities analysts and investors during the 44th Annual J.P. Morgan Healthcare Conference, which starts on January 12, 2026. As part of these meetings, the Company will use a corporate slide presentation attached as Exhibit 99.1 in this Form 8-K. This filing is made pursuant to Regulation FD to disclose significant information to investors and analysts. The meetings and the information being shared are intended to enhance investor relations and provide insights into the Company's strategic direction and operations.
- : Galecto Appoints Sherwin Sattarzadeh as Chief Operating Officer and Dr. Becker Hewes as Chief Medical Officer
- : SEC 8-K (5.02): On January 6, 2026, the Company announced the appointment of Sherwin Sattarzadeh as Chief Operating Officer, effective from January 5, 2026. Mr. Sattarzadeh, who has over 20 years of experience in drug development, comes from Blueprint Medicines Corporation, where he held various roles, culminating as Chief Business Officer. He will receive an annual base salary of $540,000, with a target bonus of 40%. His offer letter includes severance terms that provide for 12 months' salary if terminated without cause, increasing to 18 months under certain conditions related to a sale event. Additionally, he will receive an initial grant of 190,376 restricted stock units vesting annually over four years, contingent upon continued employment.
- : Galecto
Damora Therapeutics, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Venture | $285.0M |
| Nov 2020 | Venture | $64.2M |
| Jan 2020 | Venture | $79.1M |
Leadership
- Hans Schambye, Executive Officer, Director
- Karen Wagner, Director
- Chao Khuong, Director
- Erez Chimovits, Director
- Chandra Leo, Director
- Soren Moller, Director
- Soren Lemonius, Director
- Carl Goldfischer, Director
- Stephan Christgau, Director
- David Shapiro, Director
- Amit Munshi, Director
- Jennifer Jarrett, Chief Executive Officer
Verified email and direct lines for Damora Therapeutics, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Damora Therapeutics, Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Damora Therapeutics, Inc. in the news
- Galecto Announces Acquisition of Damora Therapeutics - Yahoo Finance (Nov 10, 2025)
- Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis - MarketBeat (Mar 19, 2026)
- Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer - Yahoo Finance (May 05, 2026)
- Galecto (NASDAQ: GLTO) outlines Damora acquisition, $285M PIPE and Cayman redomestication - Stock Titan (Dec 16, 2025)
Companies similar to Damora Therapeutics, Inc.
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Inhibitor Therapeutics · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Kinnate Biopharma · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Elevation Oncology · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Immuneering · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
About Damora Therapeutics, Inc.: questions and answers
What does Damora Therapeutics, Inc. do?
Galecto is a clinical-stage biotechnology company developing novel small-molecule therapeutics that target the core biological drivers of fibrosis, inflammation, and cancer. Founded by leading scientists and biotech executives with more than a decade of research into galectin biology and LOXL2 modulation, the company has built deep expertise in pathways central to complex and often devastating dis
Where is Damora Therapeutics, Inc. headquartered?
Damora Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States.
How many employees does Damora Therapeutics, Inc. have?
Damora Therapeutics, Inc. has about 18 employees.
Has Damora Therapeutics, Inc. raised funding?
Yes. Fundz has recorded 3 funding events for Damora Therapeutics, Inc.. The most recent, $285.0M, was in Nov 2025.
Who leads Damora Therapeutics, Inc.?
Jennifer Jarrett is a Chief Executive Officer at Damora Therapeutics, Inc..
What is the latest news on Damora Therapeutics, Inc.?
On Jul 20, 2026, SEC 8-K (1.01):
Is Damora Therapeutics, Inc. a public company?
Yes. Damora Therapeutics, Inc. is publicly traded under the ticker DMRA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy